Authors
Jeannette Nilsen, Kine M K Sand, Hana J Al-Khabbaz, Lennart Maximilian van Ligtenberg, Simone Mester, Line Mathiesen, Hanna T Noordzij, Kjell-Rune Jensen, Nils Leitzinger, Oda Ottersen, Sopisa Benjakul, Marie Leangen Herigstad, Fulgencio Ruso-Julve, Aina Karen Anthi, Anders Moen, Mari Nyquist-Andersen, Torleif Tollefsrud Gjølberg, Eirin Listau Bertelsen, Jason Cameron, Stian Foss, Gregory J Christianson, Tilman Schlothauer, Tor Brynjar Stuge, Lisbeth E Knudsen, Inger Sandlie, Derry C Roopenian, Maria Therese Ahlen, Jan Terje Andersen
Published in
Science immunology. Volume 11. Issue 122. Pages eaee5151. Aug 14, 2026. Epub Aug 14, 2026.
Abstract
Immunoglobulin G (IgG)-based monoclonal antibodies are effective therapies for cancer, autoimmune diseases, and migraine. However, they are actively transported across the placenta by the neonatal Fc receptor (FcRn), limiting their use during pregnancy. Using mouse models and an ex vivo human placental perfusion system, we show that although FcRn binds albumin independently of IgG, albumin is not transported to the fetus in mice or across human placental tissue. Fusion of IgG to albumin markedly reduced transplacental transport in both models while preserving the prolonged plasma half-life conferred by FcRn. Similarly, fragment antigen-binding fragments fused to engineered albumin with enhanced FcRn binding showed minimal fetal exposure. In a mouse model of fetal and neonatal alloimmune thrombocytopenia, albumin fusion of an anti-human platelet antigen IgG reduced fetal antibody transfer and attenuated thrombocytopenia in the offspring. These findings identify albumin as an attractive fusion partner for biologics intended to minimize fetal exposure during pregnancy.
PMID:
42600043
Bibliographic data and abstract were imported from PubMed on 15 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 20
- Comments 0